Sang-Hoon Kim
President at BUKWANG PHARMACEUTICAL CO., LTD.
Net worth: 2 M $ as of 2024-05-30
Sang-Hoon Kim active positions
Companies | Position | Start | End |
---|---|---|---|
BUKWANG PHARMACEUTICAL CO., LTD. | Director/Board Member | 2010-03-01 | - |
President | 2013-03-14 | - | |
Chief Executive Officer | 2013-03-14 | - | |
Corporate Officer/Principal | 2010-03-01 | 2014-06-26 | |
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Director/Board Member | - | - |
Dyna Therapeutics Co., Ltd. | Director/Board Member | - | - |
Career history of Sang-Hoon Kim
Training of Sang-Hoon Kim
Boston University | Undergraduate Degree |
Statistics
International
South Korea | 3 |
United States | 2 |
Denmark | 2 |
Operational
Director/Board Member | 3 |
Chief Executive Officer | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
BUKWANG PHARMACEUTICAL CO., LTD. | Health Technology |
Private companies | 2 |
---|---|
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
Dyna Therapeutics Co., Ltd. |
- Stock Market
- Insiders
- Sang-Hoon Kim
- Experience